Zum Inhalt springen
Home » Melanoma: IO Biotech Updates on Pivotal Phase 3 Trial

Melanoma: IO Biotech Updates on Pivotal Phase 3 Trial

Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma